towards improved death receptor targeted therapy for ... - TI Pharma
towards improved death receptor targeted therapy for ... - TI Pharma towards improved death receptor targeted therapy for ... - TI Pharma
TRAIL‐induced migration and invasion Cell Signal 2010; 22(3):377‐385. 42. Van Schaeybroeck S, Kelly DM, Kyula J, Stokesberry S, Fennell DA, Johnston PG et al. Src and ADAM‐17‐mediated shedding of transforming growth factor‐alpha is a mechanism of acute resistance to TRAIL. Cancer Res 2008; 68(20):8312‐8321. 43. Elrod HA, Lin YD, Yue P, Wang X, Lonial S, Khuri FR et al. The alkylphospholipid perifosine induces apoptosis of human lung cancer cells requiring inhibition of Akt and activation of the extrinsic apoptotic pathway. Mol Cancer Ther 2007; 6(7):2029‐2038. 44. Kandasamy K, Srivastava RK. Role of the phosphatidylinositol 3'‐kinase/PTEN/Akt kinase pathway in tumor necrosis factor‐related apoptosis‐inducing ligand‐induced apoptosis in non‐small cell lung cancer cells. Cancer Res 2002; 62(17):4929‐4937. ‐ 81 ‐
Chapter 4 ‐ 82 ‐
- Page 31 and 32: Chapter 2 adhesion molecules [109].
- Page 33 and 34: Chapter 2 Reference List 1. Ashkena
- Page 35 and 36: Chapter 2 37. Tolcher AW, Mita M, M
- Page 37 and 38: Chapter 2 melanoma cells from TRAIL
- Page 39 and 40: Chapter 2 and ERK pathways. Circula
- Page 41 and 42: Chapter 3 ABSTRACT Tumor necrosis f
- Page 43 and 44: Chapter 3 inhibitors and TRAIL rece
- Page 45 and 46: Chapter 3 of amplification of the t
- Page 47 and 48: Chapter 3 P38 and JNK have opposing
- Page 49 and 50: Chapter 3 Figure 2 (continued). (e)
- Page 51 and 52: Chapter 3 previously established H4
- Page 53 and 54: Chapter 3 effect on TRAIL‐induced
- Page 55 and 56: Chapter 3 induced apoptosis in H460
- Page 57 and 58: Chapter 3 Reference List 1. Jemal A
- Page 59 and 60: Chapter 3 40. Domina AM, Vrana JA,
- Page 61 and 62: Chapter 4 ABSTRACT Tumor necrosis f
- Page 63 and 64: Chapter 4 role in the activation of
- Page 65 and 66: Chapter 4 the tip with a diameter o
- Page 67 and 68: Chapter 4 RESULTS TRAIL induces a s
- Page 69 and 70: Chapter 4 vehicle control or with 5
- Page 71 and 72: Chapter 4 Non‐canonical TRAIL res
- Page 73 and 74: Chapter 4 A549‐shRIP1 cells clear
- Page 75 and 76: Chapter 4 Figure 7. Inhibition of S
- Page 77 and 78: Chapter 4 DISCUSSION The TRAIL rece
- Page 79 and 80: Chapter 4 Src‐independent mechani
- Page 81: Chapter 4 variants. Cell Death Dis
- Page 85 and 86: Chapter 5 ABSTRACT TRAIL is an inte
- Page 87 and 88: Chapter 5 targets and subsequent pr
- Page 89 and 90: Chapter 5 RESULTS Synergistic activ
- Page 91 and 92: Chapter 5 ng/ml TRAIL (Fig. 3B). Ap
- Page 93 and 94: Chapter 5 by sub‐G1 levels in the
- Page 95 and 96: Chapter 5 DISCUSSION In the present
- Page 97 and 98: Chapter 5 Reference List 1. Jemal A
- Page 99 and 100: Chapter 5 ‐ 98 ‐
- Page 101 and 102: Chapter 6 ABSTRACT TRAIL is a tumor
- Page 103 and 104: Chapter 6 various stress stimuli [1
- Page 105 and 106: Chapter 6 Subsequently, the membran
- Page 107 and 108: Chapter 6 B H460 A549 Figure 1. Rep
- Page 109 and 110: Chapter 6 TRAIL‐dependent cell de
- Page 111 and 112: Chapter 6 B H460 A549 C Figure 4 (c
- Page 113 and 114: Chapter 6 Figure 5 (continued). Mec
- Page 115 and 116: Chapter 6 regulation and checkpoint
- Page 117 and 118: Chapter 6 mechanism of immune evasi
- Page 119 and 120: Chapter 7 ABSTRACT Thymidine phosph
- Page 121 and 122: Chapter 7 Figure 1. Schematic overv
- Page 123 and 124: Chapter 7 that was measured before
- Page 125 and 126: Chapter 7 RESULTS TdR conversion to
- Page 127 and 128: Chapter 7 dR is secreted from the c
- Page 129 and 130: Chapter 7 Figure 4. Accumulation of
- Page 131 and 132: Chapter 7 angiogenic properties. Ho
Chapter 4<br />
‐ 82 ‐
Change language